CriticalProkinetic, peripheral dopamine D2 receptor antagonist×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
Voriconazole is a strong CYP3A4 inhibitor and can raise the levels of drugs that this enzyme metabolises (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). In the liver, CYP3A4 is the main enzyme that metabolises domperidone, and drugs that markedly inhibit this enzyme may raise its plasma level (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Both drugs are associated with QT prolongation, and torsade de pointes has been reported rarely with voriconazole (voriconazole SmPC, EMA). Epidemiological studies link domperidone to a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs or CYP3A4 inhibitors (domperidone SmPC, AEMPS). The documents do not say how much voriconazole raises domperidone levels.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With domperidone, QT prolongation and torsade de pointes have been reported very rarely (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With voriconazole, torsade de pointes has been reported rarely in people with risk factors such as previous cardiotoxic chemotherapy, cardiomyopathy, low potassium and concomitant medicines (voriconazole SmPC, European Medicines Agency, EMA). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with strong CYP3A4 inhibitors regardless of their own effect on the QT interval and names voriconazole among the systemic azole antifungals (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The European voriconazole SmPC contraindicates voriconazole with drugs known to prolong the QT interval when voriconazole may raise their levels through CYP3A4. Its examples do not include domperidone, but according to its own SmPC domperidone prolongs the QT interval, and CYP3A4 is the main enzyme that metabolises it (voriconazole SmPC, European Medicines Agency, EMA; domperidone SmPC, AEMPS). Domperidone is also contraindicated in known QT prolongation, significant electrolyte disturbances and heart disease such as congestive heart failure (domperidone SmPC, AEMPS). Check potassium, magnesium and calcium before and during voriconazole treatment and correct any disturbance (voriconazole SmPC, EMA, and label, US Food and Drug Administration, FDA). Use voriconazole with caution in QTc prolongation, cardiomyopathy, particularly with heart failure, sinus bradycardia and symptomatic arrhythmias (voriconazole SmPC, EMA). If domperidone and voriconazole have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (domperidone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins; DailyMed setid ce3ef5cf-3087-4d92-9d94-9eb8287228db
- EMA: Ficha técnica: Voriconazol (EU/1/02/212), sección 4.5 (2026)– EMA SmPC vía AEMPS CIMA, nº 02212015 (EU/1/02/212), secciones 4.2, 4.4 y 4.5, consultado 10/2026
- EMA: Ficha técnica: Voriconazol (EU/1/02/212), sección 4.4 (2026)– EMA, VFEND 200 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 02212015, consultado 14/10/2026, sin fecha de revisión en CIMA, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Domperidona (nº registro 55411), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55411 (Motilium 1 mg/ml suspensión oral, Esteve), revisión 09/2025, secciones 4.2, 4.3, 4.4 y 4.5